Pentax rejects Ambu's claims of head start

The pandemic has created a market frenzy for single-use bronchoscopes. Pentax Medical denies that Ambu has a head start over its closest international rivals.

Photo: Pentax / PR

According to Pentax Medical, the pandemic has accelerated the demand for medical products that can be used without the risk of infection, increasing the competition on the global market for single-use endoscopes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs